Key result
Gestational hypertension was associated with significantly reduced placental eNOS and iNOS mRNA levels and significantly higher NO and ONOO(-) production compared to healthy controls.
Why the study?
Are placental eNOS and iNOS gene expression and NO/ONOO(-) levels altered in patients with gestational hypertension compared to healthy pregnant controls?
Case-Control (n=30)
Are placental eNOS and iNOS gene expression and NO/ONOO(-) levels altered in patients with gestational hypertension compared to healthy pregnant controls?
Gestational hypertension is associated with reduced placental eNOS and iNOS gene expression but increased NO and ONOO(-) production, suggesting altered NO metabolism and potential oxidative damage.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for NO pathway dysregulation in gestational hypertension; should not yet change clinical practice.
OBJECTIVE: Hypertension is one of the most common medical disorders in pregnancy and a role of nitric oxide (NO) metabolism has been described. Thus, the present work aimed at determining placental gene expression of eNOS and iNOS, to measure NO and ONOO(-) levels in patients with gestational hypertension (GH). METHODS: Fifteen patients with GH and 15 healthy pregnant controls were enrolled in the study. Placental tissue was taken immediately after delivery and was stored at -80 °C until analysis. A piece of frozen tissue was homogenized in the appropriate buffer. Total RNA was extracted and was reverse transcribed to obtain complementary DNA that was used for real-time PCR for iNOS and eNOS expression, whereas NO and ONOO(-) production were measured by commercially available kits. RESULTS: Placental eNOS and iNOS mRNA levels were significantly reduced in GH when compared to controls. NO and ONOO(-) production were both significantly higher in GH than controls. CONCLUSIONS: The reduced eNOS and iNOS gene expression in women with GH reinforces the hypothesis that the mechanisms involving NO pathways, may promote oxidative damage, by contributing to the reduced blood flow and increased resistance in the feto-maternal circulation and suggests the use of NO modulators as useful tools in GH management.
No takes yet. Share an insight, caveat, or question.
Vignini et al. (2015) conducted a case-control in Gestational hypertension (n=30). Gestational hypertension vs. Healthy pregnant controls was evaluated on Placental gene expression of eNOS and iNOS, and NO and ONOO(-) levels. Gestational hypertension was associated with significantly reduced placental eNOS and iNOS mRNA levels and significantly higher NO and ONOO(-) production compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: